SF1019 Patent infringement or is it?

A forum to discuss Aimspro (Goat Serum) as a possible therapy for MS

SF1019 Patent infringement or is it?

Postby Nemotoday » Sun Feb 15, 2009 11:16 am

Has anyone seen this or can shed some light on it?


http://immunosyn.wordpress.com/2008/09/ ... ou-decide/



Patent infringement?

I am a stockholder of Immunosyn and are angry at the without substance posts, both here and on other boards about the alleged patent infringement. I have spent the last two days researching this and I hope that some will read my comments. On the stock price and legal problems with the Argyll team I know very little, but will hang in there.

rOn for example makes the following claim.
“Daval International have been developing their treatment - Aimspro for much longer then Argyl. SF1019 is a copy which will soon be exposed via court proceedings”

These claims are spurious to say the least, very easy to disprove and I wonder where he got his information and what his real motivation is.

A few simple web searches will reveal:
That Daval International Ltd (Company No. 04009385) was incorporated in the UK on the 7th June 2000 and first called Wide Target Ltd, changing to Davis Daval Ltd when Dr Gary Davis of “Goat Doctor” fame was with them and finally to its current name in 2002.

Source:
http://wck2.companieshouse.gov.uk/03524 ... ompdetails
Argyll patents

Now using 7th June 2000 when Daval was formed as a starting point, just do a search here

http://patft.uspto.gov/netahtml/PTO/search-adv.htm

You will find two granted patents one of which clearly shows Argyll as the assignee and that the other was applied for on September 19th 2000 and is part of the the basis for the second etc:

1. Composition and method for immunostimulation in non- mammalian vertebrates
Abstract
This invention relates to compositions utilized to modulate the immune system of non-mammalian vertebrates. More particularly, the present invention relates to the use of low molecular weight substantially immunoglobulin free fractions isolated from mammals to induce a stimulated immune response in non-mammalian vertebrates.

Inventors: Ansley; Daniel R. (Ottawa, KS), Willeford; Kenneth O. (Starkville, MS)
Appl. No: 09/666,009 Filed: September 19, 2000 (This means the prior art date)
Granted: April 6, 2004
NOTE: The prior art date was about two months after Davis Daval was incorporated.

2. Prophylactic and therapeutic benefits of a new class of immune stimulating peptides
Inventors: Thacker; James D. (Marietta, OH), Fuhrer; J. Peter (Dayton, OH), Willeford; Kenneth O. (Starkville, MS)

Abstract
A new class of lipopeptides has been surprisingly discovered from mammalian serum that are potent immunoregulators, hereinafter, referred to as Immune Cell Potentiating Factors (”ICPF”s). The clinical and laboratory data show a wide range of prophylactic and therapeutic applications for the ICPFs including primary and adjunctive therapy in the treatment of diseases of both bacterial and viral origin as well as certain neoplastic diseases. Described herein are chemical structures of ICPF of the invention, the likely mode of action, and the surprisingly broad spectrum of therapeutic efficacy and wide margin of safety to the host species.

Patent number: 7,358,044 Filed: April 16, 2004 (This means the prior art date)
Granted: April 15, 2008 Assigned to: Argyll Biotechnologies LLC

I also found this application which Argyll probably own:
United States Patent Application 20050042635 Inventors: Thacker, James D. ; et al. Filed February 24, 2005
Prophylactic and therapeutic benefits of a new class of immune stimulating peptides
Abstract

A new class of lipopeptides has been surprisingly discovered from mammalian serum that are potent immunoregulators, hereinafter, referred to as Immune Cell Potentiating Factors (”ICPF”s). The clinical and laboratory data show a wide range of prophylactic and therapeutic applications for the ICPFs including primary and adjunctive therapy in the treatment of diseases of both bacterial and viral origin as well as certain neoplastic diseases. Described herein are chemical structures of ICPF of the invention, the likely mode of action, and the surprisingly broad spectrum of therapeutic efficacy and wide margin of safety to the host species.

Inventors: Thacker, James D.; (Marietta, OH) ; Fuhrer, J. Peter; (Dayton, OH) ; Willeford, Kenneth O.; (Starkville, MS)

None of the above mentions hyper immune serum and only refer to natural goat serum. It would appear that the two fully granted ICPF patents and the last application form the basis for what is now called SF1019.

Daval patents
I also searched the European patent office and found lots of applications, some of which were binned by them or rejected by the patent office, but could not find any granted patents in the name of Davis Daval Ltd, Daval International Ltd, or Aimsco Ltd, who it is claimed have licensed Aimspro to Daval.

Aimsco was formed on the 17th July 2003 and I also found a reference to a company called Ice Biologics Ltd in some of their applications. In other words neither Daval nor Aimsco, appear to own any intellectual property by way of an awarded patent.

More

Now we know from the patent applications that Aimspro is made from a hyper immune goat serum and that ICPF or SF1019 as it now appears to be known has a fully granted patent and although coming from a goat is not made from a hyper immune serum. The only thing in common appears to be the goat.

Quite clearly SF1019 or ICPF has been developed from a solid novel scientific base and some might want to Google Kenneth Willeford as he has published a number of peer reviewed papers including one on the use of ICPF in horses which Argyll seem to hold the patent for and in one form was approved by the USDA some years ago for the treatment of horses.

http://www.colorado-serum.com/probio_home.html

“Efficacy studies demonstrate that Pulmo-Clear [Caprine Serum Fraction, Immunomodulator], when used with adjunctive therapy, successfully clears Equine Lower Respitory Disease (ELRD), leading to increased recovery rates and reduced recovery times in affected horses.* In fact, combined data from field studies show that Pulmo-Clear helps promote an overall ELRD recovery rate as high as 86 percent”.

I wonder if the Daval product called Ceremben has any similarities?

http://www.davalinternational.com/ceremben.php

It seems to me that as Argyll appear to own or have licenses for the use of the fully granted patents relating to an entirely different product to that of Daval. Aimspro and SF1019 cannot then be the same, unless it is the other way around and Daval are breaching the Argyll patents.

No patent infringement suit would on this basis hold up in court against Argyll, so why then should these apparently unsupported claims be made? Are these posters trying to damage the stock price even more and if so, is this not a criminal offence?

Other bits

One of the Dr Gary Davis FAILED patent applications: (Lots more if you search)
Inventor Name: Davis, Gary R. Inventor City: Tulsa Inventor State: OK
Publication Number: US 20020086022 A1 Publication Date: 04 July 2002
Title: Neutralizing antibody and immunomodulatory enhancing compositions
Application Number: 20020086022

Abstract

A composition and method for immune modulation of pathogenic infections is disclosed. More particularly, a composition and method for enhancing a mammal’s ability to respond to, e.g., immunosuppressive pathogens, is disclosed in which a target antigen is mixed with a heterologous antisera specific or cross-reactive to that antigen to produce an inoculant. The inoculant is used to cause natural and specific immune responses to the heterologous antibodies to enhance complement fixation and specific humoral and cellular responses.

Googled BB7075 and found this very interesting site:
http://www.qassia.com/new-aids-treatmen ... in-extract

It comes from November 2003 and appears to tell us how to make BB7075, using methods very similar to the Daval patent applications and others made by the now deceased Dr Gary Davis personally from about 1995 onwards. A dead virus called HIV13b is mentioned in the Aimspro patent applications, the website and in the failed Davis applications.

HIV13b is the bit which is injected into the goat to create the hyper immune reaction and this strongly suggests to me that if Daval are also using HIV13b to create their hyper immune reaction, then the whole hyper immune based Aimspro and Gary Davis enchilada is probably non patentable as it has been in the public domain since before Argyll Biotechnologies LLC was set up.

The website says
First you must acquire a goat. The female goat has an easier disposition and is recommended to use. The purpose of the goat is to manufacture Polycolonial Antibodies. The Polycolonial Antibody is required to stop AIDS from fusion in a human, thus eliminating the virus and restoring the quality of life.
PRE MANUFACTURING STEPS TO: BB7075
This can be achieved by contacting a VIROLOGIST and requesting that they obtain and make up killed AIDS virus. The virologist would contact ABI in Maryland. He would place an order to purchase the following “Killed Viruses”. ( HIV 13b, HIV 1mn, HIV2 NIHzn) Each CC would cost approximately $1,500.00 dollars. You will need .3cc of each virus to make up the amount to be given to the goat. This mixture is then given to a VETERINARIAN to be injected into a goat.
After four weeks, contact your VETERINARIAN and instruct them to remove [200cc] of blood from your goat.
See the website for more.
http://www.qassia.com/new-aids-treatmen ... in-extract
So what is really going on here, Argyll do have patents and Daval as far as I can tell do not?
Can anyone post a link to an awarded patent for Aimspro? It would sure help.

This section of the Immunosyn 10KSB is also worth remembering.

“Immunosyn’s primary asset is its exclusive worldwide license from Argyll Biotech to market, distribute and sell SF-1019. The Company also has the right of first offer to enter into additional license agreements for uses of other compounds which are not already covered under the existing license agreement. In addition to SF-1019, Argyll Biotech has licensed certain intellectual property developed by Professor Kenneth Willeford, Professor of Biochemistry and Molecular Biology, Mississippi State University”.

10KSB Here
http://msnmoney.brand.edgar-online.com/ ... ZkAoLJ6j_9

More coming

______________________________________________________________

What is really going on here???
Keep smiling as who knows what good things might be around the corner and if the road snakes a bit keep going.
User avatar
Nemotoday
Family Member
 
Posts: 72
Joined: Fri May 21, 2004 3:00 pm

Advertisement

Return to Aimspro

 


  • Related topics
    Replies
    Views
    Last post
  • SF1019
    1, 2, 3by kolob » Wed May 02, 2007 1:41 pm
    42 Replies
    29273 Views
    Last post by Peaches1 View the latest post
    Fri Oct 01, 2010 8:45 am

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service

cron